Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
26 oct. 2017 10h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...